End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 CNY | +4.48% |
|
+4.96% | -51.42% |
Jun. 26 | Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology | MT |
Jun. 18 | Walvax Terminates Coronavirus Vaccine Trials Due to Mutations | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.42% | 2.4B | |
+6.50% | 97.06B | |
+7.24% | 41.54B | |
-8.49% | 33.89B | |
+83.27% | 29.78B | |
-12.97% | 15.63B | |
-0.80% | 13.66B | |
-12.22% | 11.43B | |
+173.60% | 10.37B | |
+4.64% | 9.14B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology